Carl KestensFeb 26, 20228 min read TIML/INKMUNE MAY DRASTICALLY OUTPERFORM CIML – A COMPARISONReminder of the NK cell activation threshold as a predictor of survival This, we know. · INKmune generates memory-like NK cells in...
Carl KestensFeb 20, 202216 min readINKMUNE AS A NEW APPROACH IN NK-TARGETING IMMUNO-ONCOLOGYSummary: INKmune is an NK-targeting immuno-oncology drug allowing treatment in a wide range of NK-related cancers; INKmune’s production...
Carl KestensDec 29, 202110 min readTHE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART IV: A DEEPER DIVE INTO INKMUNEThe immuno-oncology platform INKmune of INmune Bio may be a better, easier to produce and cheaper product candidate than others.
Carl KestensDec 21, 202114 min readTHE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART III: AN INTRODUCTION TO INKMUNEINTRODUCTION As an immunotherapy drug candidate, INKmune seems by far the most commercially sustainable, undervalued that I am aware of....